- Home
- CNOB vs COGT Comparison
CNOB vs COGT Comparison
Compare CNOB & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNOB
- COGT
- Stock Information
- Founded
- CNOB 1982
- COGT 2014
- Country
- CNOB United States
- COGT United States
- Employees
- CNOB N/A
- COGT N/A
- Industry
- CNOB Major Banks
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- CNOB Finance
- COGT Health Care
- Exchange
- CNOB Nasdaq
- COGT Nasdaq
- Market Cap
- CNOB 928.9M
- COGT 984.0M
- IPO Year
- CNOB 1996
- COGT 2018
- Fundamental
- Price
- CNOB $27.09
- COGT $8.90
- Analyst Decision
- CNOB Buy
- COGT Buy
- Analyst Count
- CNOB 4
- COGT 6
- Target Price
- CNOB $26.50
- COGT $14.67
- AVG Volume (30 Days)
- CNOB 243.6K
- COGT 1.3M
- Earning Date
- CNOB 10-24-2024
- COGT 11-12-2024
- Dividend Yield
- CNOB 2.66%
- COGT N/A
- EPS Growth
- CNOB N/A
- COGT N/A
- EPS
- CNOB 1.73
- COGT N/A
- Revenue
- CNOB $248,641,000.00
- COGT N/A
- Revenue This Year
- CNOB N/A
- COGT N/A
- Revenue Next Year
- CNOB $35.98
- COGT N/A
- P/E Ratio
- CNOB $15.66
- COGT N/A
- Revenue Growth
- CNOB N/A
- COGT N/A
- 52 Week Low
- CNOB $17.07
- COGT $3.67
- 52 Week High
- CNOB $29.02
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- CNOB 56.00
- COGT 28.97
- Support Level
- CNOB $26.71
- COGT $9.97
- Resistance Level
- CNOB $29.02
- COGT $11.16
- Average True Range (ATR)
- CNOB 0.91
- COGT 0.78
- MACD
- CNOB 0.19
- COGT -0.25
- Stochastic Oscillator
- CNOB 63.24
- COGT 2.02
About CNOB ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a holding company. The company through its holding provides banking services including lending, depository, and related financial services to commercial, industrial and governmental customers. It is managed as one segment: a community bank. It generates revenue from net interest income.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.